CBD Market 'Surges' As FDA Delays Setting Regulatory Policy – NPA
Executive Summary
FDA should formalize its internal policy on CBD enforcement or create a pathway to make it compliant for use in supplements, says NPA President Daniel Fabricant. NPA and PCPC submitted comments on FDA request for input on agency's action at ongoing United Nations meeting on drug policy.
You may also be interested in...
Enforce Immediately In CBD Supplement Market, Industry Groups Suggest To FDA
FDA should go beyond warning letters to carry out inspections, import reviews and other actions on companies marketing CBD-containing supplements and foods, CHPA says. It and other consumer health trade groups urge agency to act immediately numerous businesses marketing products that could threaten public health.
CBD Market Survival-Of-Fittest Looms With FDA Regulation, Industry Standards
Number of hemp and CBD supplement marketers will shrink as passage of farm bill leads to industry certification as well as FDA enforcement. Firms practicing transparency are most likely to survive in a few years.
With High Profile At FDA, Gottlieb Headed Ambitious Consumer Health Initiatives
Scott Gottlieb claimed higher profile than most previous FDA commissioners with frequent Twitter posts and by including his remarks in many agency communications to industries and consumers. In his nearly two years in post, he also had more central role in FDA initiatives in areas such as keeping unsafe products labeled as supplements off the market and explaining why hemp and CBD are available and supplements even though FDA considers the products noncompliant as dietary ingredients.